US equities |
META $622.62 ▼-1.26% TSLA $407.12 ▲+3.96% MU $932.93 ▲+3.23% NVDA $217.84 ▲+0.85% SPCX $149.96 ▲+2.08% AMD $560.36 ▲+5.47% SNDK $1,298.81 ▲+3.44% AAPL $346.30 ▲+0.69%
FinancialContent

Xencor, Inc. - Common Stock (NQ:XNCR)

29.98 +0.80 (+2.74%)
Delayed Quote Updated: 3:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer ↗
Xencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026... 
Via MarketBeat
Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of Today's US Session ↗
Via Chartmill
News headline image
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
From Xencor, Inc.
Via Business Wire
Xencor (NASDAQ:XNCR) Beats Q2 Estimates on Royalty Settlement and Milestone Payment ↗
Via Chartmill
News headline image
Beyond The Numbers: 4 Analysts Discuss Xencor Stock ↗
 
Via Benzinga
News headline image
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at the 2026 Cantor Global Healthcare Conference
From Xencor, Inc.
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Xencor Reports Second Quarter 2026 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports First Quarter 2026 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
From Xencor, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Third Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor (XNCR) Q2 Revenue Jumps 82% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Xencor Reports Second Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >